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Simvastatin combined with bone marrow stromal cells treatment activates
astrocytes to ameliorate neurological function after ischemic stroke in rats
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Abstract: Evidence indicates that reactive astrocytes play an important role in neurological functional amelioration after stroke. Bone
marrow stromal cell (BMSC) transplantation-promoted astrocyte-derived neurotrophic factors’ expressions resulted in decreasing the
number of apoptotic neurons and improving neurogenesis and angiogenesis in the ischemic boundary zone. Recent studies found
that simvastatin had neuroprotective activity in acute stroke. However, it is still ambiguous as to whether simvastatin combined with
BMSCs can further activate astrocytes, which contribute to neurological functional recovery after ischemic stroke. In our present study,
we established a middle cerebral artery occlusion model in rats and found that combination treatment of simvastatin and BMSCs
could significantly increase neurological functional scores and induce activated astrocytes to enhance stromal cell-derived factor-1
α, vascular endothelial growth factor, brain-derived neurotrophic factor, and glial cell line-derived neurotrophic factor expressions
compared with BMSC alone (P < 0.05) by immunofluorescence staining on the 7th day after ischemia. Furthermore, western blot results
showed that combination treatment could notably activate the AKT/mammalian target of rapamycin signaling pathway in oxygen–
glucose deprivation-induced astrocytes. It was superior to BMSC treatment at the 5-min time point (P < 0.01). Therefore, we think that
combination treatment should be a more effective therapy after stroke due to synergic functions of supplementary approaches.
Key words: Astrocyte, bone marrow stromal cells, ischemic stroke, simvastatin

1. Introduction
Research indicates that astrocytes play an important role
in secreting antioxidants, regulating extracellular levels
of ions and neurotransmitters, reabsorbing glutamate for
energy substrate in support of neuronal metabolism, being
involved in the control of cerebral blood flow, participating
in regulation of blood–brain barrier (BBB) permeability,
and forming glial scars after cerebral ischemia (Sofroniew
and Vinters, 2010; Barreto et al., 2011; Kowiański et al.,
2013). Previously, Li et al. (2008) found that infarct size was
larger in glial fibrillary acidic protein (GFAP) knockout
mice than in wild-type mice, and this was attributed
to the reduction of glutamate uptake and decrease of
plasminogen activator inhibitor-1 and endothelin B
receptor expression. Under pathological conditions,
astrocytes could release neurovascular trophic factors,
e.g., glial cell line-derived neurotrophic factor (GDNF),
brain-derived neurotrophic factor (BDNF), stromal cellderived factor-1 (SDF-1), and vascular endothelial growth
factor (VEGF)-A (Miyazaki et al., 2001; Argaw et al., 2012;
* Correspondence: yhzhao@must.edu.mo

Mele and Jurič, 2014; Shin et al., 2014). As has been well
demonstrated, SDF-1, BDNF, and GDNF were capable of
activating the phosphatidylinositol 3-kinase (PI3K)/AKT
and/or extracellular signal-regulated kinase/mitogenactivated protein kinase (ERK/MAPK) signaling pathways
in glia, while the reactive PI3K/AKT signal pathway
could further improve astrocytes to express VEGF and
angiopoietin-1 (Ang1) (Lu et al., 2009; Lui et al., 2012;
Jang et al., 2014). Due to their pivotal role in the nervous
system, astrocytes are now recognized as key participants
in brain development, function, and disease.
Studies indicated that bone marrow stromal cell
(BMSC) transplantation was a promising approach for the
treatment of stroke. Intravenous BMSC administration
could significantly enhance neurological outcome, which is
related to BMSCs migrating to injured tissue and releasing
neurovascular trophic factors (Chen et al., 2001; Li et al.,
2002). Moreover, BMSCs could induce astrocytes and
mouse brain endothelial cells (ECs) to express VEGF and
Ang1, resulting in angiogenesis and vascular stabilization
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(Zacharek et al., 2007). Another study showed that
BMSCs could also activate local astrocytes to express large
amounts of GDNF, which was beneficial in attenuating the
number of apoptotic cells and improving neurogenesis in
the ischemic boundary zone (IBZ) (Shen et al., 2010).
As a 3-hydroxy-3-methylglutaryl-coenzyme A
(HMG-CoA) reductase inhibitor, simvastatin exhibits
neuroprotective action in acute stroke. Some studies
demonstrated that simvastatin could decrease infarct
volume and improve neurological function through
reducing neuronal excitotoxicity and cytotoxic edema,
decreasing oxidative stress response, protecting the
BBB, promoting angiogenesis and neurogenesis,
and
ameliorating
stroke-induced
peripheral
immunodepression after cerebral ischemia (Chen et
al., 2009; Zacharek et al., 2009; Jin et al., 2013; CamposMartorell et al., 2014; Zhu et al., 2014). Recently, some
reports found that combination treatment with simvastatin
and BMSCs more significantly improved neurological
function scores and arteriogenesis and angiogenesis and
reduced infarct volume and brain edema superior to any
single treatment method; furthermore, simvastatin could
advance BMSCs’ migration and differentiation (Cui et al.,
2009; Xu et al., 2009; Pirzad Jahromi et al., 2012). However,
the exact effects and mechanism of simvastatin combined
with BMSC treatment on astrocytes after ischemic stroke
are still indistinct and need to be elucidated. In this
research, we investigated whether combination treatment
with simvastatin and BMSCs could enhance reactive
astrocytes to express SDF-1α, VEGF, BDNF, and GDNF in
the IBZ, and mediate astrocytes’ Akt/ mTOR and ERK 1/2
pathways in the therapeutic procedures.
2. Materials and methods
2.1. Materials
Simvastatin was obtained from Sigma Chemical Co.
(USA). Astrocytes were supplied by the American Type
Culture Collection (ATCC); GIBCO Dulbecco’s modified
Eagle medium/F12 (DMEM/F12) was the product of
Life Technologies (USA). Primary antibodies for CD44PE, CD90-PE, CD45-FITC, and CD34-PerCP were from
Santa Cruz Biotechnology (USA). Primary antibodies of
GFAP, stromal cell-derived factor-1α (SDF-1α), BDNF,
GDNF, and VEGF were obtained from Abcam (UK);
primary antibodies of AKT, p-AKT, mTOR, p-mTOR,
ERK 1/2, and p-ERK 1/2 were products of Cell Signaling
Technology, Inc. (USA). The other materials and reagents
were from commercial sources.
2.2. BMSC culture and identification
BMSCs were isolated from fresh complete bone marrow
of 3-week-old male Sprague Dawley (SD) rats’ tibias
and femurs (n = 4), and the culture protocol was done
according to our previous report (Zhao et al., 2013). In
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general, the cells were cultured with DMEM/F12 cell
medium supplemented with 10% fetal bovine serum and
1% penicillin-streptomycin for 48 h. Subsequently, cell
medium of BMSCs was replaced every 48 h and passage
was done during the cell logarithm growth period with
cell fusion of 80%. At passage 3, digestive BMSCs were
incubated with fluorescence-conjugated antibodies
including CD44-PE, CD90-PE, CD45-FITC, CD34-PerCP,
and phosphate-buffered saline (PBS; negative control) in
a black chamber at 4 °C for 30 min. Then the cells were
washed by PBS and fixed with 4% paraformaldehyde, and
the flow cytometry with the Cellquest system (Becton,
Dickinson and Company, USA) was used to analyze purity.
2.3. Middle cerebral artery occlusion model establishment
and group division
The present investigation conforms to the National
Institute of Health Guide for the Care and Use of
Laboratory Animals (NIH Publications No. 80-23), revised
in 1996. All experimental procedures were approved by the
Institutional Animal Care and Use Committee of Macau
University of Science and Technology. Male SD rats (n =
45) weighing 240–260 g and supplied by the Laboratory
Animal Center of Sun Yat-Sen University (Guangzhou, PR
China) were anesthetized with 10% (w/v) chloral hydrate
(3.0 mL/kg, i.p.) and a permanent middle cerebral artery
occlusion (MCAo) model was established according to
the method described by Longa et al. (1989). Briefly, the
middle cerebral artery of SD rats was obstructed with a 4–0
surgical nylon suture (length of 20–22 mm, determined by
body weight) coated with polylysine, which was inserted
into the internal carotid artery from the external carotid
artery, and then a 5-point scale neurological deficit score
as reported by Yilmaz et al. (2006) was used to evaluate the
MCAo model. Only animals with a score of 2 (circling to
the right) were selected for group division. A total of 45
MCAo rats were included in this study, and the rats were
randomly divided into: 1) MCAo group (n = 15), 2) BMSC
group (n = 15), and 3) simvastatin (Sim) + BMSC group (n
= 15). One milliliter of PBS or BMSC suspension solution
(2 × 106 cells/mL) was respectively injected into rats in the
MCAo or BMSC and Sim + BMSC groups via caudal vein
at 3 h after the model establishment; simvastatin (1 mg/
kg) (Cui et al., 2009) was gavaged daily for 7 days in the
Sim + BMSC group. A sham-operated group (n = 15) was
also established to exclude the influence of the operation
process on the therapeutic effect.
2.4. Neurological functional evaluation
We evaluated neurological function in each group at 3 h and
at 1, 3, 5, and 7 days after operation following the principle
of Garcia et al.’s (1995) neurological score. The principle
include six sections: 1) evaluating animals’ spontaneous
activity; 2) symmetry of four limbs’ movements when rat
was held suspended by the tail and symmetric forepaws
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were assessed, 3) climbing wall of wire cage; 4) body
proprioception; 5) reaction to touch on either side of
the trunk; 6) response to vibrissa touch. An investigator
who was blinded to the experimental groups recorded the
scores of every group.
2.5. Immunofluorescence staining
On day 7 after the operation, the rats in the MCAo, BMSC,
and Sim + BMSC groups were sacrificed, and brains were
harvested and fixed in fresh 4% paraformaldehyde for
histological studies. Fresh frozen coronal sections of 40 µm
in thickness were cut on a cryostat microtome (Thermo
Fisher Scientific Shandon Cryotome FSE). Every 5th slice
for a total of 6 sections was used for immunohistochemical
staining. To identify whether astrocytes were activated
and expressed chemokine and neurovascular trophic
factors after stroke, antibody against GFAP (1:1000) was
respectively couple-stained with SDF-1α (1:100), VEGF
(1:200), BDNF (1:1000), and GDNF (1:20) according to
the manufacturer’s protocol. In brief, the slices were first
incubated with primary antibodies at 4 °C overnight,
followed by secondary antibodies including Alexa Fluor
488 goat antirabbit IgG (H+L) (1:200) or goat antirabbit
IgG H&L (Cy3) (1:100) preadsorbed secondary antibodies
for 1 h at room temperature. Nuclei were stained with
4’,6-diamidino-2-phenylindole (DAPI). A LSM710 laserscanning confocal microscope (Carl Zeiss, Germany)
was used to detect fluorescent labeling of every slice. Five
nonoverlapping fields of one slice at the penumbra cortex
were observed for each rat under a magnification of 10 × 10
and 10 × 40 in confocal images. Image-Pro Plus software
(Media Cybernetics) was applied to analyze the proteins’
expression. In control experiments, primary antibodies
were replaced with PBS.
2.6. Astrocytes induced by oxygen–glucose deprivation
and group division
Culture medium of astrocytes was exchanged with glucosefree feeding medium, and cells were incubated under
hypoxic atmosphere (95% N2 and 5% CO2) in an anaerobic
chamber (HP015, HITECH, P.R. China) for 1 h at 37 °C.
After oxygen–glucose deprivation (OGD), astrocytes were
immediately rinsed with PBS and the medium was replaced
with fresh DMEM/F12 feeding medium. Subsequently,
astrocytes (5 × 105 cells/mL) induced by OGD were
incubated with: 1) DMEM/F12 culture medium alone,
2) DMEM/F12 culture medium from BMSCs that had
been cultured for 12 h, and 3) conditional medium from
BMSCs that had been treated with simvastatin (1 µmol/L)
(Cui et al., 2009) for 12 h. OGD-induced astrocytes were
respectively incubated with different culture mediums for
5 min and 60 min, and western blot assay was performed to
determine p-AKT/AKT, p-mTOR/mTOR, and p-ERK1/2/
ERK1/2. Normal cultured astrocytes with DMEM/F12
were used as the control.

2.7. Western blot assay
Protein samples were extracted from cultured astrocytes
in four groups (normal group, OGD group, BMSC
group, and Sim + BMSC group) with TRIzol (Invitrogen,
USA), and protein concentration was determined by
enhanced BCA Protein Assay Kit (Beyotime Institute
of Biotechnology, P.R. China) according to the method
suggested by the manufacturer. Subsequently, protein
samples were electrophoresed on gradient sodium dodecyl
sulfate-polyacrylamide gel and electrotransferred to PVDF
membranes in Tris–glycine transfer buffer. Membranes
were blocked in 5% (w/v) nonfat dry milk for 1 h at
room temperature, followed by incubation with primary
antibodies including anti-AKT (1:1000), anti-p-AKT
(1:2000), anti-mTOR (1:1000), anti-p-mTOR (1:1000),
anti-ERK 1/2 (1:1000), and anti-p-ERK 1/2 (1:2000) at 4
°C overnight. Then the membranes were gently washed
with TBST (Tris-HCl pH 8.0, 125 mm NaCl, 0.1% Tween
20) three times and incubated with goat antirabbit IgG
(H+L) secondary antibodies (1:5000) at room temperature
for 1 h. After the final washes, the membranes were
scanned and the signals of reactive bands were quantified
using the Odyssey Infrared Imager (LI-COR Corporate,
USA). Phosphorylation levels of the targeted proteins were
analyzed by total levels of corresponding proteins. Western
blots were duplicated three independent times.
2.8. Statistical analysis
All results were expressed as means ± standard deviation.
The significance for the difference among groups was
analyzed with SPSS 19.0 (USA) by one-way analysis
of variance (ANOVA) followed by the least significant
difference (LSD) test. Differences were considered to be
statistically significant at P < 0.05.
3. Results
3.1. BMSC morphology and characterization
As illustrated in Figure 1, 72 h after the initial seeding, the
morphology of adherent cells seemed to be fibroblasticlike mononuclear cells and it took a logarithmic growth
appearance; from passage 2, the cells became uniform and
grew in whirlpool, radial, or parallel patterns. We thus
choose passage 3 of cells to identify characterization of
BMSCs by flow cytometry analysis. The results indicated
that the rate of CD34-positive cells (as a hematopoietic
stem cell marker) was 2.32%, of CD45-positive cells (as a
lymphocyte antigen) was 7.24%, and of CD44 and CD90
(both as characteristic BMSC surface markers) was as high
as 97.56% and 99.07%, respectively (Figure 2). The flow
cytometry results demonstrated that our primary BMSCs
were highly purified.
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Figure 1. BMSC morphology under microscope. A: BMSCs were primary-cultured for 72 h; B: BMSCs at passage 2 (scale bar:
200 µm).

Figure 2. BMSC phenotype identification by flow cytometry. The rate of CD34-positive cells was 2.32%,
of CD45-positive cells was 7.24%, and of CD44 and CD90 was respectively 97.56% and 99.07%.
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aggregated in the GFAP-positive (red) area in the IBZ
(Figure 5A). The quantitative analysis showed that the
expressions of SDF-1α and VEGF overlapping the GFAPpositive expression area in the Sim + BMSC group were
higher compared with those in the MCAo and BMSC
groups (P < 0.01). This suggested that combination
treatment of simvastatin and BMSCs could increase
astrocyte-derived SDF-1α and VEGF expressions. Some
research reports stated that reactive astrocytes could
express BDNF and GDNF; furthermore, transplanted
BMSCs possessed the ability to facilitate the expressions
of BDNF and GDNF in the IBZ (Chen et al., 2005; Béjot et
al., 2011; Wei et al., 2012). We observed images of GFAP
double-staining with BDNF and GDNF on the 7th day
after stroke and found that the overlaps of GFAP-positive
(red) and BDNF/GDNF-positive (green) signals were
primary distributed around the ischemic core, as shown
in the BMSC and Sim + BMSC groups. It illustrated that
BMSC could promote astrocyte-derived BDNF/GDNF
expressions and combination treatment might possess an
additive effect (Figure 5B). Quantitative analysis displayed
that simvastatin plus BMSCs could significantly enhance
BDNF and GDNF expressions in reactive astrocytes (P <
0.01 compared with MCAo and BMSC groups).
3.4. Simvastatin plus BMSCs activated OGD-induced
astrocytes’ AKT/mTOR signal cascade
To further study the intracellular mechanism of the effect
of simvastatin plus BMSCs on astrocytes, we investigated
AKT/mTOR and ERK 1/2 pathway proteins’ activation
status in astrocytes by western blot assay. As shown in

Neurological functional score

3.2. Simvastatin combined with BMSCs promoted
poststroke outcome of neurological function
To evaluate whether combination treatment with
simvastatin and BMSCs could attenuate neurological
injury after stroke, a neurological functional test was
performed. As observed in Figure 3, neurological scores
in the combination treatment group began to markedly
enhance from day 1 compared with those in the MCAo
and BMSC groups, and the increasing tendency continued
to the 7th day (P < 0.01 vs. MCAo group; P < 0.05 vs.
BMSC group). In addition, neurological scores in the
BMSC group were notably higher than those in the MCAo
group at 3 and 7 days (P < 0.05). These data indicated that
combination treatment promoted neurological functional
recovery superior to BMSC alone treatment.
3.3. Simvastatin combined with BMSCs activated
astrocytes and improved astrocyte-derived SDF-1α,
VEGF, BDNF, and GDNF expressions
As one of a family of proteins of intermediate filament,
GFAP’s expression has been regarded as the hallmark of
reactive gliosis. To test whether combination treatment
could activate astrocytes in the IBZ after stroke, GFAP
expression was measured by immunofluorescence staining.
As shown in Figure 4, GFAP-positive signals (green) in the
combination treatment group were higher compared with
those in the BMSC and MCAo groups (P < 0.01), and this
result demonstrated that simvastatin plus BMSCs could
notably activate astrocytes.
Our triple fluorescent immunostaining images
displayed that SDF-1α and VEGF (green) primarily

3h

1 day

3 days 5 days 7 days

Figure 3. Neurological functional outcome from 3 hours to 7 days post-surgery.
Garcia neurological score evaluation was performed at 3 h and 1, 3, 5, and 7
days after the operation in each group. Data as presented as mean ± standard
deviation. *P < 0.05, **P < 0.01 vs. MCAo at corresponding time; #P < 0.05 vs.
BMSC group at corresponding time.

523

ZHAO et al. / Turk J Biol

Figure 4. Combination treatment with simvastatin and BMSCs promoted astrocytes to express GFAP in the IBZ on the 7th day after
ischemic stroke. Immunofluorescence staining of GFAP (green) in the IBZ (magnification 100×) and quantitative analysis. Data are
expressed as mean ± standard deviation (n = 15). *P < 0.05, **P < 0.01 compared with MCAo; ##P < 0.01 compared with BMSC
group. The experiment was repeated 3 times, and representative pictures are shown. Scale bar: 100 µm.

Figure 5. Combination treatment with simvastatin and BMSCs enhanced reactive astrocytes to express SDF-1α, VEGF, BDNF, and
GDNF in the IBZ on the 7th day after stroke. A: Immunofluorescence staining of SDF-1α (green) and VEGF (green) overlapping GFAP
(red) in astrocytes is presented (magnification 400×); quantitative analysis of SDF-1α and VEGF expressions in GFAP-positive area.
B: Positive cells of GFAP (red) double-immunofluorescence stained with BDNF (green) and GDNF (green) (magnification 400×);
relative expressions of BDNF and GDNF in GFAP-positive area were analyzed. Data are expressed as mean ± standard deviation (n =
15). **P < 0.01 compared with MCAo; #P < 0.05, ## P < 0.01 compared with BMSC group. The experiment was repeated 3 times, and
representative pictures are shown. Scale bar: 20 µm.
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Figure 5. (Continued).

Figure 6A, phosphorylated expressions of AKT and mTOR
in the Sim + BMSC group increased significantly after 5 min
of treatment (P < 0.01 vs. BMSC and OGD groups), and
phosphorylated expression of mTOR in the Sim + BMSC
group was still higher than that in the OGD group at 60
min (P < 0.05). We concluded that simvastatin combined
with BMSC activated the AKT/mTOR pathway in OGDinduced astrocytes. We also found that combination
treatment did not enhance phosphorylated expression of
ERK 1/2 after 5 min of incubation, and moreover, the Sim
+ BMSC group obviously decreased ERK 1/2 expression in
astrocytes at 60 min (Figure 6B).
4. Discussion
Studies had demonstrated that simvastatin plus BMSCs
could improve angiogenesis and reduce infarct volume
and brain edema, which would obviously contribute to
neurological deficits amelioration after stroke (Cui et
al., 2009; Xu et al., 2009; Pirzad Jahromi et al., 2012). In
our present study, we further verified that combination
treatment with simvastatin and BMSC could promote
astrocyte-derived SDF-1α, VEGF, GDNF, and BDNF
expressions in IBZ, as well as activate the astrocytic
AKT/mTOR signal pathway, which helped to decrease
neurological functional injury.
As the most abundant nonneuronal cells in the brain,
astrocytes play important roles in cerebral ischemia.
Pekny and Pekna (2004) reported when the GFAP gene
was knocked out in transgenic mice, reactive gliosis
began to attenuate and the signs of central nervous system
degeneration became more prominent. By investigating
GFAP expression, our present study firstly confirmed

that combination treatment with simvastatin and BMSC
could significantly activate astrocytes in the ischemic zone.
Reactive astrocytes expressed a variety of chemokine and
neurovascular trophic factors including SDF-1α, VEGF,
GDNF, and BDNF, which are involved in the tolerance
of the body to severe ischemic injury, angiogenesis,
neurogenesis, and neurite outgrowth after stroke (Swanson
et al., 2004; Gao et al., 2005; Shen et al., 2010; Shin et al.,
2014).
The chemokines SDF-1α and VEGF have important
effects on the migration and angiogenesis of stem cells (e.g.,
neural progenitor cells/stem cells, endothelial progenitor
cells, and mesenchymal stem/stromal cells). Xu et al. (2007)
reported that SDF-1α and VEGF from hypoxia-induced
astrocytes could promote neural progenitor cells migration
in vitro. Moreover, SDF-1α cooperated with VEGFmodulated circulating MSCs’ recruitment and entrapment
as a vital step of neovascularization, and SDF-1α increased
VEGF expression to induce MSCs’ differentiation into ECs
from multiple approaches (Zhou et al., 2007; Wang and
Zou, 2014). Among families of neurotrophic factors, BDNF
and GDNF are found to be the major factors that improve
stroke recovery and brain plasticity after ischemia (Béjot
et al., 2011; Kuric et al., 2013). In our present study, we
demonstrated that combination treatment was obviously
capable of enhancing SDF-1α, VEGF, BDNF, and GDNF
expressions in astrocytes compared with BMSC alone
treatment. In this sense, we think that the combination
treatment indeed amplified the therapeutic effect.
To further understand the mechanism of combination
treatment effect on reactive astrocytes, we examined the
AKT/mTOR and ERK 1/2 pathways in OGD-induced

525

ZHAO et al. / Turk J Biol

A

B

Figure 6. Combination treatment of simvastatin and BMSCs activated AKT/mTOR signaling pathway in OGD-induced astrocytes.
A: Representative western blot results for p-Akt, Akt, p-mTOR, and mTOR at 5 and 60 min and quantitative analysis. B: Western blot
results and analysis of ERK1/2 proteins at 5 and 60 min in OGD-induced astrocytes. Data are expressed as means ± standard deviation.
*P < 0.05, **P < 0.01 vs. OGD; ##P < 0.01 vs. BMSC; &&P < 0.01 vs. normal.
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astrocytes in vitro. Previous reports showed that the
reactive AKT/mTOR signal pathway in astrocytes was
beneficial to regulate glutamate transporter 1 and VEGF
gene transcription (Wu et al., 2010; Sun et al., 2013).
As a major phosphorylating target of mTOR, p70S6K
is associated with apoptosis of astrocytes (Pastor et al.,
2009). Therefore, rapamycin (mTOR inhibitor) or deletion
of p70S6K1 and p70S6K2 notably promoted OGDinduced cell apoptosis in microglia or astrocytes (Pastor
et al., 2009; Shang et al., 2011). This suggested that mTOR
activation might protect astrocytes against ischemiainduced apoptosis. In addition, a study found that
microglia stimulated with SDF-1α could increase Akt and
ERK1/2 phosphorylation to regulate interleukin-6 (Lu et
al., 2009). In our present study, we found that combination
treatment with simvastatin and BMSCs dramatically
activated the Akt/mTOR signaling pathway in OGDinduced astrocytes; it should benefit to decrease glutamate
toxicity and apoptosis of astrocytes, improve therapeutic
angiogenesis, and modulate inflammation after stroke.

The efficacy of ERK1/2 activation on neuroprotection is
in dispute at present. Szydlowska et al. (2010) observed
that the inhibition of ERK1/2 contributed to attenuating
glutamate-induced death of astrocytes. Our experimental
results showed that combination treatment inhibited
the ERK1/2 pathway; it might be related to regulation of
glutamate.
In summary, our present study demonstrated that
combination treatment with simvastatin and BMSCs
could obviously improve reactive astrocytes to express
chemokine and neurovascular trophic factors, as well as
activate the astrocytic Akt/mTOR signaling pathway. All
of the above processes benefit neurological functional
recovery. Due to synergic functions of this combination
treatment method, our approach might be a more effective
therapy for ischemic stroke.
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